Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -2.22 Million AUD | -1.68% |
| 2023 | -2.18 Million AUD | 44.67% |
| 2022 | -3.95 Million AUD | -16.74% |
| 2021 | -3.38 Million AUD | 62.64% |
| 2020 | -9.07 Million AUD | -2517.48% |
| 2019 | -346.66 Thousand AUD | 81.91% |
| 2018 | -1.91 Million AUD | 53.94% |
| 2017 | -4.16 Million AUD | -102.59% |
| 2016 | -2.05 Million AUD | 42.54% |
| 2015 | -3.57 Million AUD | 29.15% |
| 2014 | -5.04 Million AUD | 31.03% |
| 2013 | -7.31 Million AUD | 0.0% |
| 2010 | -22.68 Million AUD | 24.88% |
| 2009 | -30.2 Million AUD | 15.2% |
| 2008 | -35.61 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.91 Million AUD | 0.0% |
| 2024 FY | -2.22 Million AUD | -1.68% |
| 2024 Q4 | -2.22 Million AUD | 0.0% |
| 2024 Q1 | -1.91 Million AUD | 51.66% |
| 2023 Q2 | -2.62 Million AUD | 0.0% |
| 2023 Q1 | -2.62 Million AUD | 33.61% |
| 2023 FY | -2.18 Million AUD | 44.67% |
| 2023 Q3 | -2.18 Million AUD | 16.67% |
| 2023 Q4 | -3.95 Million AUD | -80.75% |
| 2022 FY | -3.95 Million AUD | -16.74% |
| 2022 Q3 | -3.95 Million AUD | 67.3% |
| 2022 Q4 | -3.95 Million AUD | 0.0% |
| 2022 Q1 | -12.1 Million AUD | -256.99% |
| 2022 Q2 | -12.1 Million AUD | 0.0% |
| 2021 Q4 | -3.38 Million AUD | 0.0% |
| 2021 Q1 | -7.51 Million AUD | -551.32% |
| 2021 Q2 | -7.51 Million AUD | 0.0% |
| 2021 Q3 | -3.38 Million AUD | 54.88% |
| 2021 FY | -3.38 Million AUD | 62.64% |
| 2020 Q4 | 1.66 Million AUD | 0.0% |
| 2020 Q3 | 1.66 Million AUD | 185.74% |
| 2020 FY | -9.07 Million AUD | -2517.48% |
| 2020 Q2 | 582.59 Thousand AUD | 0.0% |
| 2020 Q1 | 582.59 Thousand AUD | 268.06% |
| 2019 FY | -346.66 Thousand AUD | 81.91% |
| 2019 Q4 | -346.66 Thousand AUD | 0.0% |
| 2019 Q2 | -1.85 Million AUD | 0.0% |
| 2019 Q1 | -1.85 Million AUD | 3.23% |
| 2019 Q3 | -346.66 Thousand AUD | 81.31% |
| 2018 FY | -1.91 Million AUD | 53.94% |
| 2018 Q2 | -3.36 Million AUD | 0.0% |
| 2018 Q1 | -3.36 Million AUD | 19.03% |
| 2018 Q3 | -1.91 Million AUD | 43.12% |
| 2018 Q4 | -1.91 Million AUD | 0.0% |
| 2017 Q2 | -2.07 Million AUD | 0.0% |
| 2017 FY | -4.16 Million AUD | -102.59% |
| 2017 Q4 | -4.16 Million AUD | 0.0% |
| 2017 Q1 | -2.07 Million AUD | -1.18% |
| 2017 Q3 | -4.16 Million AUD | -100.23% |
| 2016 Q2 | -1.37 Million AUD | 0.0% |
| 2016 Q4 | -2.05 Million AUD | 0.0% |
| 2016 Q3 | -2.05 Million AUD | -48.92% |
| 2016 FY | -2.05 Million AUD | 42.54% |
| 2016 Q1 | -1.37 Million AUD | 61.41% |
| 2015 FY | -3.57 Million AUD | 29.15% |
| 2015 Q3 | -3.57 Million AUD | 33.55% |
| 2015 Q2 | -5.37 Million AUD | 0.0% |
| 2015 Q4 | -3.57 Million AUD | 0.0% |
| 2015 Q1 | -5.37 Million AUD | -6.61% |
| 2014 FY | -5.04 Million AUD | 31.03% |
| 2014 Q4 | -5.04 Million AUD | 0.0% |
| 2014 Q1 | -4.46 Million AUD | 39.01% |
| 2014 Q3 | -5.04 Million AUD | -13.09% |
| 2014 Q2 | -4.46 Million AUD | 0.0% |
| 2013 Q4 | -7.31 Million AUD | 0.0% |
| 2013 FY | -7.31 Million AUD | 0.0% |
| 2013 Q1 | -9.64 Million AUD | 0.0% |
| 2013 Q2 | -9.64 Million AUD | 0.0% |
| 2013 Q3 | -7.31 Million AUD | 24.19% |
| 2010 FY | -22.68 Million AUD | 24.88% |
| 2010 Q4 | -22.68 Million AUD | 0.0% |
| 2009 Q4 | -30.2 Million AUD | 0.0% |
| 2009 FY | -30.2 Million AUD | 15.2% |
| 2008 Q4 | -35.61 Million AUD | 0.0% |
| 2008 FY | -35.61 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -163.403% |
| Acrux Limited | -1.45 Million AUD | -52.69% |
| Actinogen Medical Limited | -9.13 Million AUD | 75.621% |
| AnteoTech Limited | -5 Million AUD | 55.489% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 86.01% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 82.491% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -126.677% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 82.162% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -22.079% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 58.226% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -213.747% |
| Biome Australia Limited | -1.56 Million AUD | -42.45% |
| Biotron Limited | -386.06 Thousand AUD | -476.638% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 97.193% |
| BTC Health Limited | -2.02 Million AUD | -10.091% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 27.081% |
| CSL Limited | 15.76 Billion AUD | 100.014% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 98.369% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 98.783% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 64.125% |
| Dimerix Limited | -21.99 Million AUD | 89.877% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 88.22% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -79.764% |
| Immuron Limited | -11.48 Million AUD | 80.614% |
| Immutep Limited | -122.18 Million AUD | 98.178% |
| Imugene Limited | -91.56 Million AUD | 97.569% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 63.051% |
| Memphasys Limited | 4.13 Million AUD | 153.833% |
| Nanollose Limited | -96.22 Thousand AUD | -2213.551% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 86.977% |
| Noxopharm Limited | -2.31 Million AUD | 4.039% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 55.064% |
| Nyrada Inc. | -4.76 Million AUD | 53.323% |
| Orthocell Limited | -19.92 Million AUD | 88.827% |
| PharmAust Limited | -9.71 Million AUD | 77.083% |
| Patrys Limited | -2.24 Million AUD | 0.645% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 87.338% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 64.797% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 78.094% |
| PYC Therapeutics Limited | -65.76 Million AUD | 96.615% |
| Race Oncology Limited | -17.18 Million AUD | 87.048% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 88.015% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 34.449% |
| Starpharma Holdings Limited | -19.83 Million AUD | 88.775% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 97.896% |
| Tissue Repair Ltd | -16.44 Million AUD | 86.459% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 143.933% |